湖北供AP26113 靶向原料药价格使用方法及供应信息

武汉帝康医药 原料药厂家 供应优质AP26113高含量原料药 欢迎来电

中文名称：AP26113 

CAS号：1197958-12-5

含量：99%

分子式：C26H34ClN6O2P

分子量：529.01

作用：AP26113是一种有效的ALK抑制剂，用于ALK突变阳性的非小细胞肺癌。

存储条件：2 year -20°C powder, 2 week 4°C in DMSO6 month -80°C in DMSO

体外研究：

AP26113 is highly active against both sensitive and resistant H3122 cells, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis in a dose dependent manner. AP26113 decreases p-ALK in the H3122 and H3122 CR cells, with IC50 values of 7.4 versus 16.8 nM, respectively. AP26113 decreases cell number in Ba/F3 cells expressing either native or mutant EML4-ALK with IC50 of 10 nM and 24 nM, respectively. AP26113 inhibits cell growth of SU-DHL-1, H3122 and Ba/F3-EML4-ALK v1 cell lines with GI50 of 9 nM, 4 nM and 13 nM, respectively. AP26113 inhibits phosphorylation of ALK with IC50 of 3.2 nM, 1.5 nM and 2.1 nM in Karpas-299, SU-DHL-1 and L-82 cell lines. AP26113 dose-dependently inhibits phosphorylation of ALK and ERK in Karpas-299 and H3122 cells. AP26113 inhibits cell growth with IC50 of 11 nM and 16 nM in Ba/F3 line (native EML4-ALK) and Ba/F3 line (EML4-ALK G1269S mutants). AP26113 inhibits ALK phosphorylationh with IC50 of 74 nM and 335 nM in Ba/F3 line (native EML4-ALK) and Ba/F3 line (EML4-ALK E1210K mutants). AP26113 (10 mg/kg-75 mg/kg) is efficacious in PF-02341066-resistant EML4-ALK mutant mouse xenograft models. AP26113 induces regression of tumors expressing native EML4-ALK and the G1269S and L1196M mutants at 25 mg/kg, 50 mg/kg and 50 mg/kg, respectively. AP26113 inhibits EGFR phosphorylation and viability with IC50 of 75 nM and 114 nM, respectively, in Ba/F3 cells expressing EGFR-DEL. AP26113 inhibits EGFR phosphorylation and viability with IC50s of 15 and 281 nM, respectively, in Ba/F3 cells expressing EGFR-DEL/T790M. AP26113 inhibits EGFR phosphorylation with an IC50 of 62 nM and cell growth with a GI50 of 165 nM in a NSCLC line expressing EGFR-DEL (HCC827). AP26113 inhibits EGFR phosphorylation with an IC50 of 59 nM and cell growth with a GI50 of 245 nM in HCC827 cells expressing EGFR-DEL/T790M. AP26113 potently inhibits SLC34A2-ROS-driven signaling and proliferation in a dose dependent manner in HCC78 NSCLC cells.

AP26113是一种有效的ALK抑制剂，IC50为0.62 nM，可克服由于L1196M突变介导的Crizotinib抵抗作用。AP26113高度有效作用于敏感型和耐药型H3122细胞，降低细胞生长，抑制ALK磷酸，并诱导细胞凋亡，这种作用存在剂量依赖性。AP26113作用于H3122 和 H3122 CR 细胞,降低p-ALK，IC50分别为7.4 和 16.8 nM。AP26113作用于表达野生型或突变型EML4-ALK的Ba/F3 细胞，降低细胞数，IC50分别为10 nM 和 24 nM。

FDA 授予 Ariad 肺癌药物 AP26113 突破性治疗药物资格

武汉帝康医药原料有限公司，是一家专注于化工产品研发和生产的企业，竭诚为客户提供优质的产品和服务。帝康医药拥有强力的研发和管理团队严格把关产品质量，为客户提供人性化的服务，以及多样化的包装规格和优于市场的价格。

公司始终秉承价格存之本的宗旨，以过硬的质量和优良的价格体系维护和拓展市场，最大限度的满足客户的需求。帝康医药，欢迎您来电来函，期待与您合作！！

AZD9291 AZD3759  WZ4002  卡博替尼  实验室直供，需要的联系